This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
$1 buys you full access to ALL of TheStreet's Subscription Services! Learn More

Drugs

November 21 Premarket Briefing: 10 Things You Should Know

U.S. stock futures rise; China's central bank cuts interest rates; ECB President Mario Draghi hints the ECB could take more aggressive stimulus measures; Alibaba's bond offering is priced.

11/21/14 - 06:58 AM EST

Biotech Stock Mailbag: Northwest Bio, Celldex, Puma, MannKind

Biotech columnist Adam Feuerstein answers readers' questions about health care.

11/21/14 - 06:00 AM EST

Try Jim Cramer's Action Alerts PLUS
Halliburton Buys Baker, Actavis Snares Allergan & Stanton's Big Deal

Halliburton Buys Baker, Actavis Snares Allergan & Stanton's Big Deal

Halliburton announced it will buy fellow oil services giant Baker Hughes this week for about $35 billion in cash and stock.

11/20/14 - 04:15 PM EST

Cramer Explains Why He Likes Agios Pharmaceuticals (AGIO)

Cramer says Agios Pharmaceuticals is unique and different and yesterday its experimental cancer drug delivered some strong results in patients with advanced leukemia.

11/19/14 - 12:31 PM EST

Foundation Medicine Winning Increased Insurance Coverage for Genetic Cancer Tests

Foundation Medicine Winning Increased Insurance Coverage for Genetic Cancer Tests

  • Tickers in this article:
  • FMI

Coverage decisions are still likely to slowly build over time but it is a clear positive that we are seeing the early adopters start to reimburse for Foundation's cancer tests.

11/19/14 - 11:17 AM EST

Clovis Lung Cancer Update Swings Momentum to Rival, Slightly

Clovis Lung Cancer Update Swings Momentum to Rival, Slightly

  • Tickers in this article:
  • CLVS
  • AZN

Healthcare investors are watching closely the race between Clovis and AstraZeneca to develop competing, targeted lung cancer drugs.

11/19/14 - 09:38 AM EST

Agios Cancer 'Metabolism' Drug Clears Bone Marrow of Leukemic Cells

Agios Cancer 'Metabolism' Drug Clears Bone Marrow of Leukemic Cells

The experimental drug from Agios, designed to attack the "metabolism" of cancer cells, has demonstrated early but strong clinical responses in a study involving patients with advanced leukemia.

11/18/14 - 06:02 PM EST

U.S. Producer Prices Rise 0.2% in October From Previous Month

Inflation picked up in October due to higher prices that U.S. companies received for new model cars, beef, pork, pharmaceuticals and electric power.

11/18/14 - 03:50 PM EST

Goldman Sachs Cements Status as Top Adviser for Global M&A Volume

Goldman Sachs cemented its status as the number one financial adviser for global mergers & acquisitions volume, at $873 billion year-to-date, according to Thomson Reuters.

11/18/14 - 01:57 PM EST

Cramer: Zoetis Defends Against Takeover; GoPro Is Going Higher

Cramer: Zoetis Defends Against Takeover; GoPro Is Going Higher

TheStreet's Jim Cramer says Zoetis' $500 million buyback is a defense tactic to prevent a takeover, while shares of GoPro are headed higher despite its secondary offering.

11/18/14 - 10:55 AM EST

Teva, Fedex Shares Look Fantastic, Arch Coal Headed Lower

Teva, Fedex Shares Look Fantastic, Arch Coal Headed Lower

Shares of Teva remain relatively inexpensive despite the stock's sharp move higher this year, said Andrew Ver Planck, portfolio manager for the MainStay International Opportunities Fund.

11/17/14 - 05:36 PM EST

S&P 500 at Record-High Close on M&A Activity, Nasdaq Ends Lower

No big moves on Wall Street but the S&P 500 still managed to close at a record high Monday.

11/17/14 - 04:55 PM EST

Actavis Announces Deal to Acquire Botox Maker Allergan for $66B

  • Tickers in this article:
  • ACT
  • AGN

Actavis is finalizing a $66 billion deal to buy Botox-maker Allergan for a combination of cash and stock.

11/17/14 - 01:40 PM EST

Teva, Fedex Shares Look Fantastic Says MainStay Fund Manager

Shares of Teva Pharmaceuticals remain relatively inexpensive despite the stock's sharp move higher this year, said Andrew Ver Planck, portfolio manager for the MainStay International Opportunities Fund.

11/17/14 - 01:26 PM EST

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
DOW 17,810.06 +91.06 0.51%
S&P 500 2,063.50 +10.75 0.52%
NASDAQ 4,712.97 +11.1030 0.24%

Brokerage Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs